Tagged with Funding

Portugal Health Cluster Portugal is currently spearheading a EUR 90 million EU post-COVID Recovery and Resilience Plan (RRP) project in Portugal focused on smart health, secondary use of data, and clinical trials. Executive Director Joaquim Cunha highlights the ways in which COVID acted as a catalyst for healthcare transformation more broadly,…

Hong Kong Hong Kong Exchanges and Clearing Limited (HKEX) chief executive Nicolas Aguzin has stepped down after a term fraught with upheaval. Having survived COVID-19 isolation, under Aguzin HKEX was confronted with strict regulatory crackdowns and has seen a drop in funds raised from initial public offerings by almost 40 percent. Newly…

Hong Kong Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and healthcare companies in 2021. “[Last year’s listings] made us rank first by number of deals and second by the amount…

Hong Kong Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a large extent by new biotech listings.   “Biotechnology is today the fastest-growing IPO market segment,” says Nicolas Aguzin, CEO of HKEX, one of the world’s major…

Hong Kong With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar 2020 for the Exchange and what the recent appointment of a new CEO – the first foreign appointment in its history – means for the…

Singapore Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy, government funding towards innovative life sciences start-ups and spin-offs has dramatically increased. These companies have greater access to funds, both from state actors as well as via private equity and public listings, but barriers…

China Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach differs from that of its competitors, and how he plans to make the firm into “China’s Genentech.”   We want…

Switzerland Fabian Gerber of SIX Swiss Exchange, Switzerland’s principal stock exchange, outlines the importance of life sciences companies to the exchange, representing over a third of total market capitalization with the presence of Roche, Novartis, Lonza and many others; explains why biotech companies are choosing to go public at later stages…

Singapore Professor Ng Huck Hui of A*Star’s Biomedical Research Council outlines the evolution of Singapore’s science and technology research and innovation ecosystem over the past 20 years and why the country is now focusing on translational science and building up enterprise.   During the past 20 years, we have built clusters…

Singapore Dr Piers Ingram, PhD, co-founder, and CEO of Singapore-based biotech Hummingbird Bioscience, shares his motivation for establishing the company in 2015, their proprietary Rational Antibody Discovery (RAD) technology platform, and rich pipeline of clinical assets in global development.   As we are able to now understand biological systems much better…

Global The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the history of the pharmaceuticals industry. Not only do innovative therapies such as CAR-T herald a shift towards genuinely individualized medicine and an exciting new front in the war against cancer,…

Norway John-Arne Røttingen, CEO of The Research Council of Norway shares his career journey from academia to industry, outlines his new role as Norway’s Global Health ambassador and gives his thoughts on Norway’s biotech and life sciences future.    On a country by country basis, Norway has had the highest proportion…